Anavex Life Sciences (AVXL) Other Accumulated Expenses (2020 - 2025)

Anavex Life Sciences has disclosed Other Accumulated Expenses across 6 years of filings, most recently posting $2.0 million for Q2 2025.

• Other Accumulated Expenses for Q2 2025 came in at $2.0 million, down 10.23% year-over-year; the trailing twelve-month figure through Jun 2025 was $2.0 million (down 10.23% YoY), and the FY2024 annual result was $1.9 million, down 27.93% from the prior year.
• Other Accumulated Expenses came in at $2.0 million for Q2 2025 at Anavex Life Sciences, up from $1.6 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $2.6 million in Q3 2023 to a low of $1.5 million in Q1 2024.
• The 5-year median for Other Accumulated Expenses is $2.1 million (2022), against an average of $2.1 million.
• Across the five-year window, Other Accumulated Expenses grew 27.26% in 2023 and dropped 27.93% in 2024, its largest moves.
• Anavex Life Sciences' Other Accumulated Expenses stood at $2.2 million in 2021, then gained by 14.07% to $2.5 million in 2022, then retreated by 16.55% to $2.1 million in 2023, then increased by 20.33% to $2.5 million in 2024, then dropped by 18.69% to $2.0 million in 2025.
• The last three Other Accumulated Expenses figures came in at $2.0 million (Q2 2025), $1.6 million (Q1 2025), and $2.5 million (Q4 2024), per Business Quant data.